Loading…
← CockpitCompetitor Analysis › 000813.SZ Dezhan Healthcare Co., Ltd. Class AOpen in the cockpit ↗

Dezhan Healthcare Co., Ltd. Class A000813.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major
Momentum weak 23
Mkt cap
$825M
US dollars, full cap
Free float
56%
of shares outstanding
$/day
$11.1M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-14.7 pp
WACC 8.0%
Hurdle
n/a
no reverse DCF
Close · CNYCN¥2.66
1D-1.9%
1W-8.6%
1M-15.3%
3M-26.5%
6M-32.8%
YTD-30.7%
1Y-39.7%
ATR %3.7%
52w lowhigh43.8% off high

What Dezhan Healthcare does

Employees: 1,195

Dezhan Healthcare at a glance

Size Dezhan Healthcare (000813.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $825M, the 2525th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥2.66 on 18 Nov 2026.

Performance Over six months the shares fell 32.8%, against -7.9% for the median peer and -20.0% for the China market (cap-weighted) — 4th lowest of 19 in its peer set.

Growth Revenue fell 10.3% over the last twelve months (peer median +7.7%); the operating margin is -120.8% (peer median 10.0%).

Valuation It trades at 13.8× enterprise value to sales against a peer median of 2.9× (3rd most expensive of 17).

Capital Return on invested capital runs 14.7 points below its cost of capital (8.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 91000813.SZ 65
Six months, rebased to 100: Dezhan Healthcare against the median of its 20 peers (local-currency closes).

Dezhan Healthcare financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥349MCN¥393MCN¥463MCN¥487MCN¥561M
Revenue growth—-15%-5%-13%—
Gross profitCN¥215MCN¥164MCN¥246MCN¥235MCN¥259M
EBITDAn/a-CN¥129M-CN¥510,070CN¥25.4M-CN¥60.3M
Net income-CN¥388M-CN¥345M-CN¥20.4MCN¥83.3M-CN¥47.0M
Free cash flow-CN¥270M-CN¥231M-CN¥181M-CN¥31.9MCN¥127M
Capital expenditureCN¥222MCN¥236MCN¥167MCN¥160MCN¥67.6M
Total debtCN¥129MCN¥135MCN¥18.1MCN¥7.57MCN¥24.8M

Quarterly statements and history in the cockpit →

Dezhan Healthcare competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%-25%0%+25%+50%-50%-25%0%+25%6032290020823002676078COLLSUVEN688621688073RIGL688176SANOFI086450ORIC069620GUDCRVSIRWD000813.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Dezhan Healthcare is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%0×250×500×750×6032290020823002676078SUVEN688176086450GUD000813.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Dezhan Healthcare is the large dot.

Dezhan Healthcare competitors and peer comparison

How Dezhan Healthcare compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Dezhan Healthcare against its 20 peers (data as of 18 Nov 2026)
Measure000813.SZPeer medianRank in peer set
1-month return-15.3%-7.0%5th lowest of 20
6-month return-32.8%-7.9%4th lowest of 19
Distance from 52-week high-43.8%-34.1%8th lowest of 20
Revenue growth (TTM)-10.3%+7.7%3rd lowest of 18
Operating margin-120.8%10.0%4th lowest of 18
EV / Sales13.8×2.9×3rd most expensive of 17
ROIC minus cost of capital-14.7 pp-0.7 pp3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Dezhan Healthcare 000813.SZChina$825M-33%-10%-121%13.8×n/an/a
Zhejiang Ausun Pharmaceutical 603229.SSChina$824M-34%+1%0%6.5×n/an/a
Wanbangde Pharmaceutical 002082.SZChina$823M-52%-38%-10%7.0×27.7%-39.5%
Hunan Er-Kang Pharmaceutical 300267.SZChina$829M-40%-14%-29%4.7×n/an/a
Hygeia Healthcare 6078.HKHong Kong$811M-3%+2%14%1.8×4.6%+22.5%
Collegium Pharmaceutical COLLUnited States$806M-24%+8%15%2.3×-2.6%+20.3%
Suven Life Sciences SUVEN.NSIndia$803M-1%+55%-4,452%789.4×n/an/a
Beijing Sun-Novo Pharmaceutical Research 688621.SSChina$849M-8%-1%-2%5.8×n/an/a
Bide Pharmatech 688073.SSChina$801M+10%+10%19%3.1×13.9%+27.7%
Rigel Pharmaceuticals RIGLUnited States$801M+48%+2%26%2.5×1.5%+22.1%
Jiangsu Yahong Meditech 688176.SSChina$854M-20%+15%-172%15.3×n/an/a
Sanofi India SANOFI.NSIndia$797M0%-6%26%4.1×16.3%-8.7%
DongKook Pharmaceutical 086450.KSSouth Korea$855M+9%+13%10%1.2×-4.2%+10.6%
Oric Pharmaceuticals ORICUnited States$795M-9%n/an/an/an/an/a
Daewoong Pharm 069620.KSSouth Korea$856M-33%+9%12%1.2×n/an/a
Knight Therapeutics GUD.TOCanada$792M+41%+36%6%1.8×6.6%+17.7%
Corvus Pharmaceuticals CRVSUnited States$860M-16%n/an/an/an/an/a
Kaken Pharmaceutical 4521.TJapan$860M-8%+5%10%0.9×n/an/a
Ironwood Pharmaceuticals IRWDUnited States$791M+22%+18%63%2.6×n/an/a
Bambusa Therapeutics BBTXUnited States$791Mn/an/an/an/an/an/a
City Therapeutics CTYUnited States$861Mn/a+388%-442%n/an/an/a

Questions

Which companies are Dezhan Healthcare's closest peers?
The cockpit's peer set: Zhejiang Ausun Pharmaceutical (603229.SS), Wanbangde Pharmaceutical (002082.SZ), Hunan Er-Kang Pharmaceutical (300267.SZ), Hygeia Healthcare (6078.HK), Collegium Pharmaceutical (COLL), Suven Life Sciences (SUVEN.NS), Beijing Sun-Novo Pharmaceutical Research (688621.SS), Bide Pharmatech (688073.SS).
Is Dezhan Healthcare expensive compared with its peers?
On ev / sales it trades at 13.8× against a peer median of 2.9×, 3rd most expensive of 17 in its peer set.
How has Dezhan Healthcare stock performed?
Over six months to 18 Nov 2026 the shares returned -32.8% against -7.9% for the median peer; over one year -39.7%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.